VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00025129
First received: October 11, 2001
Last updated: July 17, 2013
Last verified: March 2004

October 11, 2001
July 17, 2013
March 2001
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00025129 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
A Phase I Trial of VNP4010M, A Novel Alkylating Agent for Patients With Advanced or Metastatic Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced solid tumors or lymphomas.

OBJECTIVES:

  • Determine the maximum tolerated dose of VNP40101M in patients with advanced solid tumors or lymphomas.
  • Determine the toxic effects of this drug in these patients.
  • Determine the pharmacokinetics of this drug in these patients.
  • Determine the anti-tumor effects of this drug in these patients.

OUTLINE: This is a dose-escalation study.

Patients receive VNP40101M IV over 15 minutes on day 1. Treatment repeats every 4 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 1-6 patients receive escalating doses of VNP40101M until the maximum tolerated dose (MTD) is determined. The MTD is defined as the highest dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.

PROJECTED ACCRUAL: Approximately 20-30 patients will be accrued for this study.

Interventional
Phase 1
Primary Purpose: Treatment
  • Lymphoma
  • Small Intestine Cancer
  • Unspecified Adult Solid Tumor, Protocol Specific
Drug: laromustine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
May 2004
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically confirmed advanced and/or metastatic solid tumor or lymphoma for which no curative or standard effective therapy exists
  • Measurable or evaluable metastatic disease
  • No other hematologic malignancy
  • No large pleural, pericardial, or peritoneal effusions
  • No requirement for immediate palliative treatment, including surgery
  • No symptomatic brain metastases or metastases with substantial edema

    • Asymptomatic brain metastases or primary CNS disease allowed if neurologic deficits are stable

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • ECOG 0-1

Life expectancy:

  • At least 3 months

Hematopoietic:

  • Granulocyte count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hematocrit at least 30% (transfusion allowed)
  • No active uncontrolled bleeding

Hepatic:

  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • ALT and AST no greater than 1.5 times ULN (3 times ULN if liver metastases present)
  • Alkaline phosphatase no greater than 1.5 times ULN (3 times ULN if liver or bone metastases present)
  • PT and aPTT no greater than 1.5 times ULN
  • Albumin at least 2.5 g/dL

Renal:

  • Creatinine no greater than 2.0 mg/dL

Cardiovascular:

  • Ejection fraction at least 45%
  • No active heart disease
  • No myocardial infarction within the past 3 months
  • No symptomatic coronary artery disease
  • No arrhythmias requiring medication
  • No uncontrolled congestive heart failure

Pulmonary:

  • DLCO and FEV_1 at least 60% of predicted
  • No dyspnea with minimal to moderate exertion

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after study participation
  • HIV negative
  • No active infection
  • Persistent stable chronic toxic effects from prior therapy allowed if no greater than grade 1
  • No bleeding diathesis (e.g., active peptic ulcer disease)

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • At least 3 weeks since prior biologic agents and recovered
  • At least 6 months since prior high-dose chemotherapy regimen with stem cell support

Chemotherapy:

  • See Biologic therapy
  • At least 3 weeks since prior cytotoxic agents (6 weeks for nitrosoureas or mitomycin) and recovered

Endocrine therapy:

  • At least 2 weeks since prior hormonal therapy and recovered

Radiotherapy:

  • At least 3 weeks since prior radiotherapy and recovered

Surgery:

  • See Disease Characteristics
  • At least 2 weeks since prior surgery and recovered

Other:

  • No other concurrent standard therapy for cancer
  • No other concurrent investigational agents
  • No concurrent disulfiram (Antabuse)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00025129
VION-CLI-011, CDR0000068919, NCI-V01-1669
Not Provided
Not Provided
Vion Pharmaceuticals
Not Provided
Study Chair: Mario Sznol, MD Vion Pharmaceuticals
National Cancer Institute (NCI)
March 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP